In the first quarter of fiscal year 2010 ending March 2011, net income of the Japanese pharmaceutical company Astellas decreased by 10% to 39.5 billion yen (455 million US dollars) due to the appreciation of the yen and the introduction of generic drugs Prograf and Harnal .